Last update 08 May 2025

Zai Lab Ltd. (United States)

Subsidiary Company|California, United States

Overview

Tags

Skin and Musculoskeletal Diseases
Other Diseases
Neoplasms
Antibody drug conjugate (ADC)
Monoclonal antibody

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Neoplasms3
Endocrinology and Metabolic Disease2
Immune System Diseases1
Top 5 Drug TypeCount
Monoclonal antibody2
Antibody drug conjugate (ADC)2
Top 5 TargetCount
LRRC15(Leucine-rich repeat-containing protein 15)1
FGFR2(Fibroblast growth factor receptor 2)1
IL-17A(Interleukin 17A)1
DLL3 x Top I1

Related

4
Drugs associated with Zai Lab Ltd. (United States)
Bemarituzumab
Target
FGFR2
Mechanism
FGFR2 antagonists
Active Org.
Amgen, Inc.Amgen, Inc. [+2]
Originator Org.
Five Prime Therapeutics, Inc.Five Prime Therapeutics, Inc.
Active Indication
FGFR2b positive gastroesophageal junction cancer [+12]
Inactive Indication
Esophageal Carcinoma [+4]
Drug Highest PhasePhase 3
First Approval Ctry. / Loc.-
First Approval Date-
ZL-1102
Target
IL-17A
Mechanism
IL-17A inhibitors
Active Org.
Zai Lab Ltd. (United States) [+2]
Originator Org.
Zai Lab (Shanghai) Co., Ltd.Zai Lab (Shanghai) Co., Ltd.
Active Indication
Plaque psoriasis
Inactive Indication-
Drug Highest PhasePhase 2
First Approval Ctry. / Loc.-
First Approval Date-
ZL-1310
Target
DLL3 x Top I
Mechanism
DLL3 inhibitors [+1]
Active Org.
Zai Lab Ltd. (United States) [+2]
Originator Org.
Suzhou Medilink Therapeutics Ltd.Suzhou Medilink Therapeutics Ltd.
Active Indication
Solid tumor [+3]
Inactive Indication-
Drug Highest PhasePhase 1/2
First Approval Ctry. / Loc.-
First Approval Date-
4
Clinical Trials associated with Zai Lab Ltd. (United States)
NCT06885281
/ Not yet recruitingPhase 1/2
A Phase Ib/II, Open-label, Multi-center Study of ZL-1310 in Participants With Selected Solid Tumors
NCT06380907
/ RecruitingPhase 2
A Randomized, Double-Blind, Vehicle-Controlled, Multicenter, Dose-Ranging, Phase 2 Study to Evaluate the Efficacy and Safety of Different Doses of ZL-1102 Topical Gel (A Human VH IL-17A Antibody Fragment) in the Treatment of Chronic Plaque Psoriasis
NCT06179069
/ RecruitingPhase 1
An Open-label, Multicenter Study of ZL-1310 to Evaluate the Safety, Tolerability, and Pharmacokinetics in Subjects With Small Cell Lung Cancer
100 Clinical Results associated with Zai Lab Ltd. (United States)
Login to view more data
0 Patents (Medical) associated with Zai Lab Ltd. (United States)
Login to view more data
100 Deals associated with Zai Lab Ltd. (United States)
Login to view more data
100 Translational Medicine associated with Zai Lab Ltd. (United States)
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 19 May 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Preclinical
1
2
Phase 1 Clinical
Phase 2 Clinical
1
Login to view more data

Current Projects

Drug(Targets)IndicationsGlobal Highest Phase
ZL-1102
 ( IL-17A )		Plaque psoriasis
More
Phase 2
ZL-1310
 ( DLL3 x Top I )		Extensive stage Small Cell Lung Cancer
More
Phase 1
Bemarituzumab
 ( FGFR2 )		Advanced gastric carcinoma
More
Phase 1
ZL-6201
 ( LRRC15 )		Chondrosarcoma
More
Preclinical
Login to view more data

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free